Two Sigma Investments LP Purchases Shares of 12,523 TransMedics Group, Inc. (NASDAQ:TMDX)

Two Sigma Investments LP bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 12,523 shares of the company's stock, valued at approximately $781,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after acquiring an additional 40,860 shares in the last quarter. FIL Ltd grew its stake in TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP purchased a new position in TransMedics Group during the 4th quarter valued at about $57,493,000. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock valued at $48,191,000 after buying an additional 8,954 shares in the last quarter. Finally, Wasatch Advisors LP grew its stake in shares of TransMedics Group by 83.3% in the 4th quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock valued at $27,518,000 after buying an additional 200,603 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock worth $1,512,613 over the last 90 days. Insiders own 7.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $125.11.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $2.02 during trading hours on Wednesday, reaching $142.88. The company had a trading volume of 978,136 shares, compared to its average volume of 1,361,209. The stock has a 50-day moving average of $105.77 and a two-hundred day moving average of $81.57. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $4.83 billion, a PE ratio of 152.00 and a beta of 2.10. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.35 earnings per share. Analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.